|
This webcast combines presenter's video and audio with slides. View
in a 1024x768-resolution. Minimal requirements: Windows 98SE or higher,
Internet Explorer 5.0 or higher, Media Player 7.0 or higher , Powerpoint.
If Powerpoint older than 2002 (XP) or 2003, you will be asked to install
Microsoft's viewer . Select the desired presentation.Then, click on
"Play". Any trouble? Click here
|
 |
Produced
by
 |
|
A Bayer-Schering Parallel symposium at ESCP 2009: Rivaroxaban between clinical expeience and economic benefit |
|||
 |
Introduction Georges Zelger, Yverdon-Les-Bains, Switzerland |
 |
Tools for Improving the Underuse of VTE Prophylaxis among Hospitalised Patients Nils Kucher, Bern, Switzerland |
 |
Rivaroxaban, the first oral factor Xa inhibitor Patrick Mouret, Frankfurt, Germany |
 |
Economic implications of successful VTE prophylaxis |
ESCP 2009 Main Program |
 |
Pricing
of Drugs & Transparency in Health Care.
Richard Laing, WHO |
 |
Introduction
to multidisciplinary care |
  |
Interdisciplinary
perspectives on stroke treatment
Anne Kinnear, Gillian Mead, United Kingdom |
  |
